On the public citation graph

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

0 signed · 403 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/1529-0131(200011)43:11<2381::aid-anr1>3.0.co;2-mopenalex-snapshot
Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies
inferredcites →https://doi.org/10.1002/art.10876openalex-snapshot
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
inferredcites →https://doi.org/10.1002/art.11033openalex-snapshot
Etanercept‐induced lupus‐like syndrome in a patient with rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.1780400928openalex-snapshot
Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
inferredcites →https://doi.org/10.1007/s10067-002-0654-5openalex-snapshot
Anti-TNF-?-induced systemic lupus syndrome
inferredcites →https://doi.org/10.1016/b9-78-012433-9/01950-048xopenalex-snapshot
DRUG AND ENVIRONMENTAL LUPUS: CLINICAL MANIFESTATIONS AND DIFFERENCES
inferredcites →https://doi.org/10.1016/b978-0-323-37754-6.50094-4openalex-snapshot
Systemic Lupus Erythematosus
inferredcites →https://doi.org/10.1016/s0140-6736(02)07714-0openalex-snapshot
Drug-induced systemic lupus erythematosus associated with etanercept therapy
inferredcites →https://doi.org/10.1016/s0140-6736(99)05246-0openalex-snapshot
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
inferredcites →https://doi.org/10.1111/j.1365-2796.2003.01298.xopenalex-snapshot
Accumulation of plasma nucleosomes upon treatment with anti‐tumour necrosis factor‐α antibodies
inferredcites →https://doi.org/10.1136/ard.2003.018093openalex-snapshot
Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies
inferredcites →https://doi.org/10.1136/ard.58.2008.i65openalex-snapshot
Etanercept: therapeutic use in patients with rheumatoid arthritis
inferredcites →https://doi.org/10.1136/ard.61.4.358openalex-snapshot
Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections
inferredcites →https://doi.org/10.1136/ard.62.suppl_2.ii30openalex-snapshot
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis
inferredcites →https://doi.org/10.1159/000069965openalex-snapshot
Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy
inferredcites →https://doi.org/10.1172/jci19284openalex-snapshot
Antithrombotic activity of TNF-α
inferredcites →https://doi.org/10.1177/089719009901200407openalex-snapshot
Systemic Lupus Erythematosus
inferredcites →https://doi.org/10.4049/jimmunol.167.12.6821openalex-snapshot
In Vivo Neutralization of TNF-α Promotes Humoral Autoimmunity by Preventing the Induction of CTL

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4852286openalex-extracted
Tumor Necrosis Factor-Alpha Inhibitors-Induced Systemic Lupus Erythematosus: A Real-World Pharmacovigilance Study Based on the Faers Database
inferred← citeshttps://doi.org/10.1001/archderm.143.2.223openalex-snapshot
Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions
inferred← citeshttps://doi.org/10.1001/jama.2025.21505openalex-snapshot
A Woman With Rheumatoid Arthritis and Vesicular Rash
inferred← citeshttps://doi.org/10.1002/9780470571224.pse180openalex-snapshot
Assessment of Autoimmunity and Hypersensitivity
inferred← citeshttps://doi.org/10.1002/acr2.11271openalex-snapshot
Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1002/art.22327openalex-snapshot
Effects of short‐term infliximab therapy on autoantibodies in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1002/art.38882openalex-snapshot
Mechanisms of Tumor Necrosis Factor α Antagonist–Induced Lupus in a Murine Model
inferred← citeshttps://doi.org/10.1002/ccr3.7673openalex-snapshot
Anti‐TNFα induced lupus due to infliximab therapy in a patient with concurrent Crohn's disease
inferred← citeshttps://doi.org/10.1002/dc.24692openalex-snapshot
Lupus erythematosus eosinophil cells in a pleural effusion
inferred← citeshttps://doi.org/10.1002/ddr.20471openalex-snapshot
Anti‐tumor necrosis factor‐α therapies for immune‐mediated and inflammatory skin diseases
inferred← citeshttps://doi.org/10.1002/ibd.21362openalex-snapshot
Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease
inferred← citeshttps://doi.org/10.1002/ibd.21370openalex-snapshot
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent
inferred← citeshttps://doi.org/10.1002/jgh3.12291openalex-snapshot
Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
inferred← citeshttps://doi.org/10.1002/rcr2.1006openalex-snapshot
Anti‐ tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
inferred← citeshttps://doi.org/10.1007/978-1-60327-285-8_11openalex-snapshot
Drug-Induced Autoimmunity
inferred← citeshttps://doi.org/10.1007/978-3-031-69895-8_11openalex-snapshot
Drug-Induced Autoimmunity
inferred← citeshttps://doi.org/10.1007/978-3-319-24535-5_6openalex-snapshot
Joint Involvement in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/978-3-319-43035-5_1openalex-snapshot
Introduction
inferred← citeshttps://doi.org/10.1007/978-3-319-68790-2_8openalex-snapshot
Skin Diseases Associated with Biologic Therapies
inferred← citeshttps://doi.org/10.1007/978-3-319-68888-6_7openalex-snapshot
Lung Histopathology in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/978-3-540-30515-6_8openalex-snapshot
Biologics bei entzündlichen Krankheiten der Haut: Wirkungsmechanismen — Möglichkeiten — Risiken
inferred← citeshttps://doi.org/10.1007/978-3-540-30515-6_9openalex-snapshot
Autoimmunphänomene unter Therapie mit Biologics
inferred← citeshttps://doi.org/10.1007/s00063-007-1104-6openalex-snapshot
Entwicklung eines systemischen Lupus erythematodes mit fokaler proliferativer Lupusnephritis unter einer Anti-TNF-α-Therapie bei Psoriasisarthritis
inferred← citeshttps://doi.org/10.1007/s00105-008-1699-4openalex-snapshot
Medikamenteninduzierter Lupus erythematodes tumidus unter Adalimumab-Therapie
inferred← citeshttps://doi.org/10.1007/s00105-010-1941-8openalex-snapshot
Biologics
inferred← citeshttps://doi.org/10.1007/s00105-017-4071-8openalex-snapshot
Secukinumab-induzierter subakut-kutaner Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00296-006-0271-8openalex-snapshot
Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results
inferred← citeshttps://doi.org/10.1007/s00296-008-0684-7openalex-snapshot
Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis
inferred← citeshttps://doi.org/10.1007/s00296-011-2016-6openalex-snapshot
Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis
inferred← citeshttps://doi.org/10.1007/s00296-012-2617-8openalex-snapshot
A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept
inferred← citeshttps://doi.org/10.1007/s00296-013-2738-8openalex-snapshot
Response to the comment by Park et al. entitled “Is there is a link between Escherichia coli septicaemia and the onset of systemic lupus erythematosus?”
inferred← citeshttps://doi.org/10.1007/s00393-025-01680-6openalex-snapshot
Umgang mit Antikörpern gegen dsDNA oder Nukleosomen unter Anti-TNF-Therapie
inferred← citeshttps://doi.org/10.1007/s00403-008-0895-5openalex-snapshot
Drug-induced lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s10067-009-1365-yopenalex-snapshot
Tumour necrosis factor inhibitor-related lupus: safety of switching agents
inferred← citeshttps://doi.org/10.1007/s10067-010-1513-4openalex-snapshot
Acrylamine-induced autoimmune phenomena
inferred← citeshttps://doi.org/10.1007/s10067-011-1924-xopenalex-snapshot
Chilblain lupus induced by TNF-α antagonists: a case report and literature review
inferred← citeshttps://doi.org/10.1007/s10067-015-3140-6openalex-snapshot
Infliximab-induced autoantibodies: a multicenter study
inferred← citeshttps://doi.org/10.1007/s10067-017-3884-2openalex-snapshot
Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature
inferred← citeshttps://doi.org/10.1007/s10067-020-05237-7openalex-snapshot
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
inferred← citeshttps://doi.org/10.1007/s10190-014-0415-8openalex-snapshot
Comment prendre en charge les douleurs ostéo-articulaires d’un patient souffrant de maladies inflammatoires chroniques intestinales ?
inferred← citeshttps://doi.org/10.1007/s10238-008-0006-0openalex-snapshot
The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients
inferred← citeshttps://doi.org/10.1007/s10238-012-0221-6openalex-snapshot
4G/5G plasminogen activator inhibitor-1 and −308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis
inferred← citeshttps://doi.org/10.1007/s10384-013-0283-3openalex-snapshot
Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy
inferred← citeshttps://doi.org/10.1007/s10384-018-0589-2openalex-snapshot
Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease
inferred← citeshttps://doi.org/10.1007/s11926-008-0072-zopenalex-snapshot
Vasculitis induced by tumor necrosis factor-targeted therapies
inferred← citeshttps://doi.org/10.1007/s11926-015-0500-9openalex-snapshot
Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?
inferred← citeshttps://doi.org/10.1007/s12026-013-8410-2openalex-snapshot
Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab
inferred← citeshttps://doi.org/10.1007/s13555-026-01930-8openalex-snapshot
Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s13665-019-0225-8openalex-snapshot
Pleurotoxic Drugs—an Update: Someone Else to Blame?
inferred← citeshttps://doi.org/10.1007/s13730-022-00756-5openalex-snapshot
Allograft adenovirus nephritis accompanied by Crohn’s disease in a kidney transplant recipient: a novel case report
inferred← citeshttps://doi.org/10.1007/s40257-015-0167-zopenalex-snapshot
Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects
inferred← citeshttps://doi.org/10.1007/s40674-019-00129-7openalex-snapshot
Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases
inferred← citeshttps://doi.org/10.1016/b978-0-08-046884-6.00629-1openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-08-100601-6.02008-1openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-12-374994-9.10022-1openalex-snapshot
Drug-Induced Lupus Mechanisms
inferred← citeshttps://doi.org/10.1016/b978-0-12-374994-9.10033-6openalex-snapshot
Drug-Induced Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-801238-3.02008-0openalex-snapshot
Immunotoxicology of Biopharmaceutics☆
inferred← citeshttps://doi.org/10.1016/b978-0-12-820583-9.00015-4openalex-snapshot
Interferons and cytokines in SLE pathogenesis and therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-06551-1.00061-0openalex-snapshot
Tumor necrosis factor blocking therapies
inferred← citeshttps://doi.org/10.1016/b978-0-323-09138-1.00063-2openalex-snapshot
Tumor necrosis factor–blocking therapies
inferred← citeshttps://doi.org/10.1016/b978-0-323-95488-4.50043-6openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-443-23947-2.00025-4openalex-snapshot
Triggers for autoimmunity
inferred← citeshttps://doi.org/10.1016/b978-0-444-53717-1.00003-2openalex-snapshot
Adalimumab
inferred← citeshttps://doi.org/10.1016/b978-0-7020-6275-9.00040-4openalex-snapshot
10.1016/b978-0-7020-6275-9.00040-4
inferred← citeshttps://doi.org/10.1016/b978-0-7020-6896-6.00089-2openalex-snapshot
Biological Modifiers of Inflammatory Diseases
inferred← citeshttps://doi.org/10.1016/b978-032305475-1.50046-xopenalex-snapshot
Treatment of Rheumatoid Arthritis: Tumor Necrosis Factor Inhibitors
inferred← citeshttps://doi.org/10.1016/b978-1-4160-5649-2.00017-2openalex-snapshot
Idiopathic connective tissue disorders
inferred← citeshttps://doi.org/10.1016/b978-2-294-71447-4.50008-8openalex-snapshot
Physiopathologie du lupus érythémateux
inferred← citeshttps://doi.org/10.1016/bs.acc.2024.10.002openalex-snapshot
Lupus nephritis: Biomarkers
inferred← citeshttps://doi.org/10.1016/j.ad.2011.01.015openalex-snapshot
Alopecia areata y terapias biológicas. Presentación de un caso asociado a adalimumab
inferred← citeshttps://doi.org/10.1016/j.ad.2011.03.002openalex-snapshot
Conectivopatías y psoriasis
inferred← citeshttps://doi.org/10.1016/j.ad.2012.09.007openalex-snapshot
Lupus eritematoso inducido por fármacos
inferred← citeshttps://doi.org/10.1016/j.adengl.2011.03.003openalex-snapshot
Connective Tissue Diseases and Psoriasis
inferred← citeshttps://doi.org/10.1016/j.adengl.2012.01.004openalex-snapshot
Alopecia Areata After Biologic Therapy: Report of a Case Related to Adalimumab
inferred← citeshttps://doi.org/10.1016/j.adengl.2012.09.025openalex-snapshot
Drug-Induced Lupus Erythematosus
inferred← citeshttps://doi.org/10.1016/j.annder.2021.02.006openalex-snapshot
Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs
inferred← citeshttps://doi.org/10.1016/j.autrev.2009.10.003openalex-snapshot
Autoimmune diseases induced by biological agents
inferred← citeshttps://doi.org/10.1016/j.autrev.2010.07.005openalex-snapshot
Drug-induced lupus: An update
inferred← citeshttps://doi.org/10.1016/j.autrev.2011.05.001openalex-snapshot
Therapeutic blockade of TNF in patients with SLE—Promising or crazy?
inferred← citeshttps://doi.org/10.1016/j.autrev.2014.05.005openalex-snapshot
Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort
inferred← citeshttps://doi.org/10.1016/j.autrev.2015.04.003openalex-snapshot
The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.autrev.2018.03.016openalex-snapshot
Drug-induced lupus: Traditional and new concepts
inferred← citeshttps://doi.org/10.1016/j.autrev.2023.103332openalex-snapshot
Tumor necrosis factor-α inhibitor-related autoimmune disorders
inferred← citeshttps://doi.org/10.1016/j.berh.2006.06.002openalex-snapshot
Problems encountered during anti-tumour necrosis factor therapy
inferred← citeshttps://doi.org/10.1016/j.biopha.2016.08.020openalex-snapshot
Application of nanoparticle technology in the treatment of Systemic lupus erythematous
inferred← citeshttps://doi.org/10.1016/j.clim.2007.08.012openalex-snapshot
TNFα blockade in human diseases: An overview of efficacy and safety
inferred← citeshttps://doi.org/10.1016/j.clim.2011.01.012openalex-snapshot
Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2007.10.030openalex-snapshot
Tumor necrosis factor antagonists in the therapy of psoriasis
inferred← citeshttps://doi.org/10.1016/j.crohns.2013.01.009openalex-snapshot
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease
inferred← citeshttps://doi.org/10.1016/j.ejphar.2009.10.025openalex-snapshot
Infliximab therapy for patients with inflammatory bowel disease: 10years on
inferred← citeshttps://doi.org/10.1016/j.ekir.2025.10.018openalex-snapshot
Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence
inferred← citeshttps://doi.org/10.1016/j.foodres.2015.05.029openalex-snapshot
Antioxidant and immunoregulatory activity of polysaccharides from adzuki beans (Vigna angularis)
inferred← citeshttps://doi.org/10.1016/j.gcb.2008.03.002openalex-snapshot
Utilisation pratique des anticorps monoclonaux anti-TNF au cours des maladies inflammatoires de l’intestin
inferred← citeshttps://doi.org/10.1016/j.gtc.2014.05.002openalex-snapshot
Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2015.12.045openalex-snapshot
Antioxidant and immunoregulatory activity of alkali-extractable polysaccharides from mung bean
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109269openalex-snapshot
The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jaad.2007.01.040openalex-snapshot
Drug-induced lupus erythematosus in a patient treated with adalumimab
inferred← citeshttps://doi.org/10.1016/j.jaad.2007.08.030openalex-snapshot
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis
inferred← citeshttps://doi.org/10.1016/j.jaad.2008.10.060openalex-snapshot
Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review
inferred← citeshttps://doi.org/10.1016/j.jaad.2008.12.001openalex-snapshot
Thrombocytopenia associated with the use of anti–tumor necrosis factor–α agents for psoriasis
inferred← citeshttps://doi.org/10.1016/j.jaad.2018.06.057openalex-snapshot
Psoriasis: Which therapy for which patient
inferred← citeshttps://doi.org/10.1016/j.jaad.2020.12.010openalex-snapshot
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
inferred← citeshttps://doi.org/10.1016/j.jaci.2015.10.023openalex-snapshot
Alterations in immune function with biologic therapies for autoimmune disease
inferred← citeshttps://doi.org/10.1016/j.jaut.2014.01.005openalex-snapshot
Diagnosis and classification of drug-induced autoimmunity (DIA)
inferred← citeshttps://doi.org/10.1016/j.jbspin.2008.09.010openalex-snapshot
Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.jbspin.2008.12.008openalex-snapshot
Anti-TNFalpha blockers, autoantibodies and autoimmune diseases
inferred← citeshttps://doi.org/10.1016/j.jbspin.2010.02.033openalex-snapshot
Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report
inferred← citeshttps://doi.org/10.1016/j.jbspin.2018.08.003openalex-snapshot
Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database
inferred← citeshttps://doi.org/10.1016/j.jbspin.2021.105174openalex-snapshot
Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
inferred← citeshttps://doi.org/10.1016/j.lpm.2009.02.006openalex-snapshot
Traitements anti-TNFα dans les maladies auto-immunes et/ou inflammatoires systémiques
inferred← citeshttps://doi.org/10.1016/j.mayocp.2012.04.011openalex-snapshot
Vasculitis Associated With Tumor Necrosis Factor-α Inhibitors
inferred← citeshttps://doi.org/10.1016/j.medcli.2009.04.035openalex-snapshot
Lupus inducido por fármacos
inferred← citeshttps://doi.org/10.1016/j.molmed.2015.12.002openalex-snapshot
The Changing Landscape of Renal Inflammation
inferred← citeshttps://doi.org/10.1016/j.nephro.2010.05.003openalex-snapshot
Néphropathie lupique stade IV chez une patiente traitée par étanercept pour un rhumatisme psoriasique
inferred← citeshttps://doi.org/10.1016/j.ophtha.2012.05.048openalex-snapshot
Infliximab Treatment of Patients with Birdshot Retinochoroidopathy
inferred← citeshttps://doi.org/10.1016/j.ophtha.2014.04.042openalex-snapshot
Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Behçet's Disease
inferred← citeshttps://doi.org/10.1016/j.rcreu.2016.10.001openalex-snapshot
Lupus cutáneo inducido por adalimumab
inferred← citeshttps://doi.org/10.1016/j.rcreue.2017.02.001openalex-snapshot
Adalimumab-induced cutaneous lupus
inferred← citeshttps://doi.org/10.1016/j.reuma.2016.08.003openalex-snapshot
Autoimmune pitfalls in treatment with TNFα inhibitors
inferred← citeshttps://doi.org/10.1016/j.reumae.2016.08.001openalex-snapshot
Autoimmune pitfalls in treatment with TNFα inhibitors
inferred← citeshttps://doi.org/10.1016/j.reval.2012.05.007openalex-snapshot
Lupus érythémateux systémique induit par l’isoniazide
inferred← citeshttps://doi.org/10.1016/j.revmed.2005.11.002openalex-snapshot
Les anti-TNF : une contre-indication ou un traitement prometteur du lupus ?
inferred← citeshttps://doi.org/10.1016/j.revmed.2006.02.005openalex-snapshot
Vascularites systémiques, syndromes auto-immuns et inhibiteurs du TNFalpha
inferred← citeshttps://doi.org/10.1016/j.revmed.2008.06.003openalex-snapshot
Lupus érythémateux cutané induit par étanercept au cours de la polyarthrite rhumatoïde
inferred← citeshttps://doi.org/10.1016/j.rhum.2008.09.021openalex-snapshot
Étude de cohorte prospective des effets de l’infliximab sur le facteur rhumatoïde, les anticorps antipeptides cycliques citrullinés et les anticorps antinucléaires chez les patients ayant une polyarthrite rhumatoïde ancienne
inferred← citeshttps://doi.org/10.1016/j.rhum.2008.12.008openalex-snapshot
Anti-TNFalpha, autoanticorps et maladies auto-immunes
inferred← citeshttps://doi.org/10.1016/j.rhum.2010.04.003openalex-snapshot
Un antécédent familial de lupus érythémateux systémique prédispose-t-il au lupus induit par anti-TNFα ? À propos d’un cas
inferred← citeshttps://doi.org/10.1016/j.rhum.2019.11.014openalex-snapshot
Sécurité des agents biologiques dans les maladies rhumatismales pédiatriques : étude rétrospective multicentrique en situation réelle dans la base de données JIRcohorte
inferred← citeshttps://doi.org/10.1016/j.sder.2006.12.002openalex-snapshot
Complications and Adverse Reactions in the Use of Newer Biologic Agents
inferred← citeshttps://doi.org/10.1016/j.sder.2010.02.002openalex-snapshot
Safety and Efficacy of the Tumor Necrosis Factor Antagonists
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2006.09.002openalex-snapshot
Treatment of Proliferative Lupus Nephritis—A Critical Approach
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2007.08.003openalex-snapshot
Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2007.10.001openalex-snapshot
Drug-Induced Arthritic and Connective Tissue Disorders
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2010.11.002openalex-snapshot
Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2019.02.003openalex-snapshot
Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2007.02.004openalex-snapshot
Functions of TNF and its Receptors in Renal Disease: Distinct Roles in Inflammatory Tissue Injury and Immune Regulation
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2015.08.007openalex-snapshot
The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis
inferred← citeshttps://doi.org/10.1016/j.suc.2019.08.011openalex-snapshot
Medical Management of Inflammatory Bowel Disease
inferred← citeshttps://doi.org/10.1016/j.tox.2004.12.025openalex-snapshot
Drug-induced lupus
inferred← citeshttps://doi.org/10.1016/j.transproceed.2008.03.102openalex-snapshot
Tumor Necrosis Factor-α Inhibitor-Induced Lupus-like Syndrome Presenting as Fever of Unknown Origin in a Liver Transplant Recipient: Case Report and Concise Review of the Literature
inferred← citeshttps://doi.org/10.1016/j.xkme.2026.101334openalex-snapshot
Interleukin-17 Inhibitors and the Potential Association of Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1016/j.yadr.2006.09.009openalex-snapshot
Issues and Advances in the Management and Pathogenesis of Cutaneous Lupus Erythematosus
inferred← citeshttps://doi.org/10.1016/s0001-7310(07)70159-xopenalex-snapshot
Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab
inferred← citeshttps://doi.org/10.1016/s0001-7310(08)74612-xopenalex-snapshot
Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab
inferred← citeshttps://doi.org/10.1016/s0025-6196(11)60668-xopenalex-snapshot
Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
inferred← citeshttps://doi.org/10.1016/s0151-9638(05)79505-3openalex-snapshot
Etanercept
inferred← citeshttps://doi.org/10.1016/s0151-9638(05)79745-3openalex-snapshot
P16 - Lupus érythémateux cutané et anti-TNFδ
inferred← citeshttps://doi.org/10.1016/s0151-9638(07)89187-3openalex-snapshot
Manifestations cutanées observées au cours d’un traitement par anti-TNF alpha : 11 observations
inferred← citeshttps://doi.org/10.1016/s0151-9638(07)91511-2openalex-snapshot
Toxidermie avec manifestations systémiques et sérologie lupique induites par l’infliximab
inferred← citeshttps://doi.org/10.1016/s0151-9638(12)70112-6openalex-snapshot
Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis
inferred← citeshttps://doi.org/10.1016/s0378-6080(10)32037-xopenalex-snapshot
Drugs that act on the immune system
inferred← citeshttps://doi.org/10.1016/s1297-319x(11)70001-xopenalex-snapshot
TNF alpha antagonist therapy and safety monitoring
inferred← citeshttps://doi.org/10.1016/s1571-5078(05)05022-1openalex-snapshot
Skin Targets for New Biological Agents in Systemic Autoimmune Diseases
inferred← citeshttps://doi.org/10.1016/s1571-5078(05)05023-3openalex-snapshot
New Trends in Topical and Systemic Immunosuppressive Treatment
inferred← citeshttps://doi.org/10.1016/s1571-5078(07)00217-6openalex-snapshot
Chapter 17 Autoimmune Hypothyroidism and Hyperthyroidism in Systemic Autoimmune Disease
inferred← citeshttps://doi.org/10.1016/s1571-5078(07)07006-7openalex-snapshot
Chapter 6 Renal Toxicities Associated with Immunomodulatory Drugs
inferred← citeshttps://doi.org/10.1016/s1577-3566(07)75607-5openalex-snapshot
Lesiones cutáneas asociadas al tratamiento anti-factor de necrosis tumoral alfa
inferred← citeshttps://doi.org/10.1016/s1578-2190(07)70539-5openalex-snapshot
Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and Adalimumab
inferred← citeshttps://doi.org/10.1016/s1578-2190(08)70191-4openalex-snapshot
Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab
inferred← citeshttps://doi.org/10.1016/s1773-035x(16)30246-5openalex-snapshot
Evolution des auto-anticorps sous biothérapies
inferred← citeshttps://doi.org/10.1016/s2255-5021(13)70049-xopenalex-snapshot
Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1038/ajg.2011.211openalex-snapshot
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety
inferred← citeshttps://doi.org/10.1038/ajg.2015.205openalex-snapshot
Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience
inferred← citeshttps://doi.org/10.1038/ki.2009.142openalex-snapshot
Immunoregulatory role of TNFα in inflammatory kidney diseases
inferred← citeshttps://doi.org/10.1038/ki.2014.285openalex-snapshot
TNF receptors: signaling pathways and contribution to renal dysfunction
inferred← citeshttps://doi.org/10.1038/ncprheum0708openalex-snapshot
Drug Insight: autoimmune effects of medications—what's new?
inferred← citeshttps://doi.org/10.1038/nrrheum.2011.35openalex-snapshot
Autoimmune-like syndromes during TNF blockade: does infection have a role?
inferred← citeshttps://doi.org/10.1038/nrrheum.2014.123openalex-snapshot
Adverse reactions to biologic agents and their medical management
inferred← citeshttps://doi.org/10.1038/s41467-025-60445-6openalex-snapshot
Type 1 interferon signature and allograft inflammatory factor-1 contribute to refractoriness to TNF inhibition in ankylosing spondylitis
inferred← citeshttps://doi.org/10.1038/s41598-025-90566-3openalex-snapshot
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
inferred← citeshttps://doi.org/10.1039/c5tb00397kopenalex-snapshot
Surface engineering of porous silicon to optimise therapeutic antibody loading and release
inferred← citeshttps://doi.org/10.1042/cs20060094openalex-snapshot
Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer?
inferred← citeshttps://doi.org/10.1055/a-0961-5054openalex-snapshot
Seltene Nebenwirkungen von biologischen DMARD
inferred← citeshttps://doi.org/10.1055/a-2853-3746openalex-snapshot
TNF-alpha Blocker-induzierte pulmonale Sarkoidose
inferred← citeshttps://doi.org/10.1055/a-2869-1756openalex-snapshot
Medikamenten-induzierter Lupus erythematodes nach TNF-α-Inhibition
inferred← citeshttps://doi.org/10.1055/s-0029-1214474openalex-snapshot
Medikamentöse Systemtherapien der Psoriasis
inferred← citeshttps://doi.org/10.1080/00325481.2017.1249266openalex-snapshot
TNF-alpha antagonist induced lupus on three different agents
inferred← citeshttps://doi.org/10.1080/00365521.2019.1663260openalex-snapshot
Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort
inferred← citeshttps://doi.org/10.1080/03009740701281293openalex-snapshot
Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma
inferred← citeshttps://doi.org/10.1080/09273948.2020.1797117openalex-snapshot
Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis
inferred← citeshttps://doi.org/10.1080/09546634.2022.2089331openalex-snapshot
Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review
inferred← citeshttps://doi.org/10.1080/2162402x.2021.1877415openalex-snapshot
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis
inferred← citeshttps://doi.org/10.1080/24725625.2020.1717741openalex-snapshot
Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile
inferred← citeshttps://doi.org/10.1093/mrcr/rxae013openalex-snapshot
Development of anti-MDA5 autoantibody-positive dermatomyositis following the use of etanercept biosimilar in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1093/ndt/gfw361openalex-snapshot
Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?
inferred← citeshttps://doi.org/10.1093/qjmed/hcq152openalex-snapshot
TNF- antagonists beyond approved indications: stories of success and prospects for the future
inferred← citeshttps://doi.org/10.1093/rheumatology/ken476openalex-snapshot
Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!
inferred← citeshttps://doi.org/10.1093/rheumatology/kep080openalex-snapshot
Anti-TNF-induced lupus
inferred← citeshttps://doi.org/10.1093/rheumatology/kep270openalex-snapshot
Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients
inferred← citeshttps://doi.org/10.1093/rheumatology/keq018openalex-snapshot
Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment
inferred← citeshttps://doi.org/10.1093/rheumatology/kes114openalex-snapshot
Assessing the safety of biologic agents in patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1093/rheumatology/kex434openalex-snapshot
Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
inferred← citeshttps://doi.org/10.1097/01.fad.0000286805.02496.4dopenalex-snapshot
Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis
inferred← citeshttps://doi.org/10.1097/01.mib.0000186408.07769.78openalex-snapshot
Infliximab Treatment Does Not Induce Organ-specific or Nonorgan-specific Autoantibodies Other than Antinuclear and Anti-Double-Stranded DNA Autoantibodies in Crohnʼs Disease
inferred← citeshttps://doi.org/10.1097/01.mib.0000435435.91988.b6openalex-snapshot
The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies
inferred← citeshttps://doi.org/10.1097/bor.0b013e3282f1331fopenalex-snapshot
Drug-induced vasculitis
inferred← citeshttps://doi.org/10.1097/bor.0b013e32832f13dbopenalex-snapshot
Drug-induced autoimmunity
inferred← citeshttps://doi.org/10.1097/mcp.0b013e3283483ea5openalex-snapshot
Biological treatments and connective tissue disease associated interstitial lung disease
inferred← citeshttps://doi.org/10.1097/md.0b013e3181441a68openalex-snapshot
Autoimmune Diseases Induced by TNF-Targeted Therapies
inferred← citeshttps://doi.org/10.1097/meg.0000000000000643openalex-snapshot
Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab
showing the first 200 of 385 · page through all 385
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.